NCT00578526 - SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

July 16, 2014

Study Completion Date

July 16, 2014

Conditions

Urothelial CancerBladder CancerAdult

Interventions

DRUG

SU011248

50 mg capsule OD PO for 28 days followed by 14 days of rest until tumor progression

DRUG

Placebo

50 mg capsule OD PO for 28 days then 14 days rest until disease progression

Trial Locations (5)

Tom Baker Cancer Centre, Calgary

Cross Cancer Institute, Edmonton

British Columbia Cancer Agency - Vancouver Centre, Vancouver

Juravinski Cancer Centre, Hamilton

London Health Sciences Centre, London